SRR8613719
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.560
- G2M_CHECKPOINT+0.540
- WNT_BETA_CATENIN_SIGNALING+0.410
- MYC_TARGETS_V2+0.390
- ALLOGRAFT_REJECTION+0.320
- MITOTIC_SPINDLE+0.320
- MYC_TARGETS_V1+0.270
- INTERFERON_GAMMA_RESPONSE+0.260
- INTERFERON_ALPHA_RESPONSE+0.250
- NOTCH_SIGNALING+0.250
Top 10 suppressed
- ANGIOGENESIS-0.440
- FATTY_ACID_METABOLISM-0.380
- ADIPOGENESIS-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
- ANDROGEN_RESPONSE-0.360
- BILE_ACID_METABOLISM-0.340
- PROTEIN_SECRETION-0.340
- MYOGENESIS-0.330
- XENOBIOTIC_METABOLISM-0.330
- HEDGEHOG_SIGNALING-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AFEA-TTM6-A-1-0-R-A741-41 | — | D | 0.843 |
| 2 | SRR1313149 | — | D | 0.843 |
| 3 | TCGA-S3-AA0Z-01A-11R-A41B-07 | — | E | 0.816 |
| 4 | C3N-00497 | — | cohortSQ1 | 0.810 |
| 5 | SRR1313128 | — | D | 0.803 |
| 6 | AUR-AE6Y-TTP1-A-1-0-R-A741-41 | — | D | 0.802 |
| 7 | TCGA-D8-A147-01A-11R-A115-07 | — | E | 0.800 |
| 8 | SRR10900596 | — | — | 0.798 |
| 9 | TCGA-96-A4JL-01A-11R-A24Z-07 | — | cohortSQ1 | 0.796 |
| 10 | SRR5088834 | — | — | 0.793 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.250 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.040 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.030 | Inavolisib | — uncovered |
| COMPLEMENT | 0.020 | Inavolisib | — uncovered |